Related Experiment Video

Updated: Nov 27, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.2K

The Roles of Base Modifications in Kidney Cancer

Chunyue Feng1,2, Xiaoli Huang1,2, Xuekun Li1,2,3

  • 1The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Frontiers in Oncology
|December 7, 2020
PubMed

Insights

Epigenetic modifications, including DNA and RNA changes, are crucial in kidney cancer development and spread. Understanding these epigenetic alterations offers new avenues for diagnosing and treating renal cell carcinoma.

Area of Science:

  • Molecular Biology
  • Oncology
  • Epigenetics

Background:

  • Epigenetic modifications, such as histone, DNA, and RNA alterations, play significant roles in biological processes and diseases.
  • Kidney cancer, particularly renal cell carcinoma, represents a common malignancy with a typically poor prognosis, necessitating further research into its molecular underpinnings.
  • Current understanding of kidney cancer's molecular mechanisms and therapeutic strategies remains incomplete, highlighting the need for in-depth investigation.

Purpose of the Study:

  • To review and synthesize recent findings on the involvement of epigenetic modifications, with a specific focus on DNA and RNA modifications, in kidney cancer.
  • To elucidate the roles of these epigenetic changes in the incidence, progression, and metastasis of kidney cancer, especially renal cell carcinomas.

Main Methods:

  • Literature review of recent studies on epigenetic modifications in kidney cancer.
  • Synthesis of current knowledge regarding DNA and RNA modifications in the context of renal cell carcinoma.

Main Results:

  • DNA and RNA modifications have recently emerged as significant factors in kidney tumors.
  • Epigenetic modifications are implicated in the initiation, advancement, and spread of kidney cancer.

Conclusions:

  • Epigenetic modifications, particularly DNA and RNA alterations, are critical factors in kidney cancer.
  • Further understanding of these mechanisms is essential for improving diagnosis and developing effective therapeutic strategies for renal cell carcinoma.
Keywords:
DNA hydroxymethylationDNA methylationRNA methylationten-eleven translocasestumor

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

2.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Renal Regulation of Acid-Base Balance01:29

Renal Regulation of Acid-Base Balance

Metabolic reactions in the body produce nonvolatile acids, such as sulfuric acid, which generate an acid load of approximately 1 mEq of H+ per kilogram of body weight daily. Excreting H+ in the urine is essential to balance this acid load.
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
1.2K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
216
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
4.6K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
151
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
88